Sponsored

Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment - Kalkine Media

Follow us on Google News:
 Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment
Image source: Company update

Highlights:

  • Prescient is developing a portfolio of targeted therapies and cell therapies for cancer treatment.
  • In September, the company joined hands with MD Anderson Cancer Center.
  • The company believes CellPryme is now ready for clinical use and third-party incorporation.
  • PTX-100 is thought to be the only geranylgeranyl transferase-1 (GGT-1) inhibitor in clinical development globally.
  • Currently, the company is studying PTX-200 for relapsed and refractory acute myeloid leukemia.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to address significant unmet needs. The company’s development portfolio comprises cell therapies and targeted therapies for a range of cancers. The company has licenced technologies and entered collaboration with renowned cancer centres in the US and Australia.

Image source: Company update

Image description: Oncology assets of PTX 

OmniCAR

OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

The company considers OmniCAR as a transformational platform for cellular immunotherapy.

In September, Prescient entered a strategic collaboration with MD Anderson Cancer Center with the goal of developing best-in-class, adaptable CAR-T cell therapies to treat haematological malignancies. MD Anderson is the largest cancer centre in the US.

The partners will test the potential of this promising TCR-like binder for blood cancers. Read more here

CellPryme-M

CellPryme-M is a novel platform designed to enhance cell therapies. The platform produces superior cells that are long lasting and with higher tumour trafficking and penetration activities.

Image source: Company update 

CellPryme-M has been manufactured at GMP grade and is ready for clinical use. As per PTX, the platform can integrate seamlessly into standard third-party programs and has revenue potential. It is also an attractive option for improving existing suboptimal CAR T products.

CellPryme-A

CellPryme-A is an adjuvant therapy that enhances tumour killing and hosts survival of conventional CAR-T cell therapies.

It overcomes the tumour’s hostile microenvironment and substantially improves the expansion CAR-T cells within the host.

Image source: Company update

The company highlights that clinical trial-ready compound is also open for third-party collaboration.  

PTX-100

The first-in-class compound licenced from Yale University, PTX-100 is believed to hold potential to block GGT-1, a key cancer growth enzyme. 

The compound, which has received Orphan Drug Designation by the US FDA for Peripheral t-cell lymphoma (TCL), is thought to be the only GGT-1 inhibitor in clinical development globally.

© 2022 Kalkine Media®, Data and image source: Company update

In Phase 1b expansion cohort in TCL, PTX-100 has demonstrated a favourable safety profile compared to its peers. Currently approved drugs for PTCL have troublesome safety profiles; however, there are no serious impacts related to PTX-100. It suits the fragile patient population and is a good candidate for combination therapy, highlights the company.

Backed by these developments, Prescient has revised the study protocol with the addition of more patients with peripheral t-cell lymphoma.

PTX-200

A novel PH domain inhibitor, PTX-200 inhibits Akt, a critical tumour survival pathway. Akt plays a major role in the development of leukemia, breast, ovarian and other cancers. 

The highly promising compound, which has secured Orphan Drug Designation from the US FDA, has a novel mechanism of action that inhibits Akt without non-specific kinase inhibition effects, thus differentiating it from other drug candidates.  

Currently, the company is studying PTX-200 for the treatment of relapsed and refractory acute myeloid leukemia in a Phase 1b/2 trial. The trial has resulted in four complete remissions so far. It is currently treating the expansion cohort at 45 mg/m2.

© 2022 Kalkine Media®, Data and image source: Company update 

PTX has witnessed significant progress in the last 12 months including

  • achieving excellent safety and efficacy data from PTX-100 and PTX-200
  • securing US FDA Orphan Drug Designation
  • developing robust and reliable manufacturing and supply agreements
  • entering important strategic and commercial partnerships

The company believes that these achievements cement its position as an emerging global leader, moving CAR-T therapies beyond their current limitations.

At the time of writing this article, PTX shares were trading at AU$0.150 midday on 5 December 2022.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK